Home > ÀǾàBU ¼Ò°³ > ¿¬Çõ
01. 27 ³Ø»çƾÁÖ¿ë¾×(¿Á»ì¸®Çöóƾ:Ç×¾ÏÁ¦) Çã°¡
02. 01 ³×¿À½ººê(Èí¼ö¼º ºÀÇÕ»ç) Çã°¡
02. 27 Á¦8ȸ ´ëÇѹα¹½Å¾à°³¹ß»ó ¿ì¼ö»ó ¼ö»ó
02. 01 Á¦³Ø¼ÖÇÇ¿¥ÁÖ Ãâ½Ã
12. 20 ´ë´öÀÇ¾à°øÀå ÁõÃà Âø°ø
12. 14 2006 º¸°Ç»ê¾÷¿ì¼ö±â¼ú´ëÀü¿¡¼­ Á¦³Ø¼Ö-PM ¡®º¸°Çº¹ÁöºÎÀå°ü»ó¡¯ ¼ö»ó ¹× ¡®¿¬±¸¼º°úȰ¿ëÃËÁø ¿ì¼ö±â°ü¡¯À¸·Î (ÁÖ)»ï¾ç»ç ¼±Á¤
09. 15 º¸°Ç»ê¾÷ÁøÈï¿ø ÁÖÃÖ ¡®2006³âµµ ÇØ¿Ü±â¼úÀÌÀü Áö¿ø»ç¾÷¡¯ Á¦³Ø¼ÖÇÇ¿¥ÁÖ ¼±Á¤
09. 01 ³×¿À¼Òºê ºÀÇÕ»ç Ãâ½Ã
07. 21 Á¦³Ø¼ÖÇÇ¿¥ÁÖ Æó¾Ï ½ÃÆÇÇã°¡ ½ÂÀÎ
07. 11 Á¦³Ø¼ÖÇÇ¿¥ÁÖ À¯¹æ¾Ï ½ÃÆÇÇã°¡ ½ÂÀÎ
05. 03 '2006 ¹ÙÀÌ¿À»ê¾÷È­ ±â¼ú°³¹ß»ç¾÷' Á¦³Ø¼ÖÇÇ¿¥ÁÖ ¼±Á¤
01. 01 »ï¾ç»ç ÀǾàÁ¤º¸½Ã½ºÅÛ ±¸Ãà
12. 30 ´ÏÄÚ½ºÅ¾Æ®·ÎŰ Ãâ½Ã
11. 17 ´ÏÄÚ½ºÅ¾Æ®·ÎŰ ǰ¸ñÇã°¡ Ãëµæ
11. 16 ³Ø»çƾÁÖ Ç°¸ñÇã°¡ Ãëµæ
07. 13 ´ë´öÀÇ¾à°øÀå ÁõÃà Áذø
06. 01 ¸ð³ëÆÐ½ºÆ® ºÀÇÕ»ç Ãâ½Ã
03. 01 ¹Ì±¹ Akina, Inc.¿Í Cetirizine FDT, "Business Agreement" ü°á
08. 30 ±¹³» Çö´ë¾àǰ°ø¾÷¢ß¿Í ¿°»ê Cetirizine FDT "R&D Agreement" ü°á
06. 14 Á¦³Ø¼ÖPM À¯¹æ¾ÏII 2»ó ¼­¿ï¾Æ»êº´¿ø µî¿¡¼­ ÀÓ»ó°³½Ã
03. 10 ¸ð³ë¼Òºê-ÇÁ·Î ºÀÇÕ»ç ǰ¸ñÇã°¡ Ãëµæ
02. 23 Á¦³Ø¼ÖÁÖ»çÁ¦ À§¾Ï ÀûÀÀÁõ Ãß°¡
12. 30 ¹Ì±¹ Akina, Inc.¿Í "R&D Agreement" ü°á
08. 21 Á¦³Ø¼ÖPM ºñ¼Ò¼¼Æ÷Æó¾Ï 2»ó ¼­¿ï´ëº´¿ø µî¿¡¼­ ÀÓ»ó°³½Ã
02. 21 Á¦³Ø¼ÖPM À¯¹æ¾ÏI 2»ó ¼­¿ï´ëº´¿ø µî¿¡¼­ ÀÓ»ó°³½Ã
02. 14 Á¦³Ø¼ÖÁÖ»çÁ¦ ³­¼Ò¾Ï ÀûÀÀÁõ Ãß°¡
12. 19 ±×¸®½º Lavipharm»ç¿¡°Ô ´ÏÄÚ½ºÅ¾ ±â¼úÀÌÀü, "R&D Agreement" ü°á
06. 10 Á¦³Ø¼ÖÁÖ»çÁ¦ Æó¾Ï ÀûÀÀÁõ Ãß°¡
05. 30 ÀǾ࿬±¸¹ýÀÎ SRC¼³¸³ (¹Ì±¹ À¯Å¸ÁÖ)
03. 27 ³­¿ë¼º¾à¹°ÇÔÀ¯ ½Ã½ºÅÛ Æ¯Çã±â¼ú»ó Áö¼®¿µ»ó ¼ö»ó(ƯÇãû, Áß¾ÓÀϺ¸)
02. 01 Á¦³Ø¼Ö-PM ¹Ì±¹ IND Çã°¡ Ãëµæ
10. 06 Á¦³Ø¼Ö-PM ÁÖ»çÁ¦ 100mg ǰ¸ñÇã°¡ Ãëµæ
06. 11 ¹Ì±¹ Akina, Inc.¿Í "Business Agreement" ü°á
03. 30 Á¦³Ø¼Ö-PM ÁÖ»çÁ¦ 30mg ǰ¸ñÇã°¡ Ãëµæ
03. 16 Á¦³Ø¼ÖÁÖ»çÁ¦ À¯¹æ¾Ï ÀûÀÀÁõ Ãß°¡
08. 30 ¹Ì±¹ Transform Pharmaceuticals, Inc.¿Í "R&D Agreement" ü°á
08. 30 ¹Ì±¹ Transform Pharmaceuticals, Inc.¿Í "Business Agreement" ü°á
08. 30 ½áÁö¼Òºê, ¹ÙÀÌ¿À¸Þ½¬ CE mark ȹµæ
03. 17 ¹Ì±¹ MacroMed, Inc.¿Í hGH, pGH, Tramadol, G-CSF, "R&D Agreement" 3°Ç
12. 23 ÀÇ·á¿ë±¸ ISO 9001 & EN 46001 ÀÎÁõ
09. 16 ¹ÙÀÌ¿À¸Þ½¬ ǰ¸ñÇã°¡ Ãëµæ
08. 26 ÀÇ·á¿ë±¸ KGMP Àû°Ý¾÷¼Ò ÀÎÁõ
12. 11 Á¦³Ø¼ÖÁÖ»çÁ¦ ǰ¸ñÇã°¡ Ãëµæ, Ãâ½Ã(2001.06.01)
12. 11 ·ù¸¶½ºÅ¾ Çöó½ºÅ¸ ǰ¸ñÇã°¡ Ãëµæ
12. 29 ½áÁö¼Òºê ºÀÇÕ»ç ǰ¸ñÇã°¡ Ãëµæ, Ãâ½Ã(1998.12.01)
05. 02 Æ®¸®¼Òºê À念½Ç»ó ¼ö»ó
01. 15 ´ÏÄÚ½ºÅ¾ ÆÐÃë ǰ¸ñÇã°¡ Ãëµæ
11. 05 ÀǾà KGMP Àû°Ý¾÷¼Ò ÀÎÁõ
08. 26 ¹Ì±¹ AmCyte, Inc¿Í "Business Agreement" ü°á
08. 26 ¹Ì±¹ VivoRx Pharmceutical, Inc.¿Í "Business Agreement" ü°á
08. 01 ¹Ì±¹ MacroMed, Inc.¿Í Gene Delivery System °³¹ß, "R&D Agreement"
03. 04 ¹Ì±¹ TheraTech, Inc.¿Í ÄÞºñÆ®¶õ-MTX, "R&D Agreement"
12. 01 ¹Ì±¹ TheraTech, Inc.¿Í ¿¡½ºÆ®¶õ-MTX, "R&D Agreement"
10. 01 ºÀÇÕ»ç Æ¯Çã±â¼ú»ó ¼ö»ó
06. 28 ¹Ì±¹ TheraTech, Inc.¿Í ¾Øµå·Î´ý-LRS, ¾ØÁö´ý-MTX ÆÐÃë, "R&D Agreement"
01. 27 ¹Ì±¹ MacroMed, Inc.¿Í "Business Agreement" ü°á
10. 01 ºÀÇÕ»ç KT(Korean Technololgy) ¸¶Å© ÀÎÁ¤
09. 01 ÀǾ࿬±¸¼Ò ¼³¸³
 
>>>>>>